Nonalcoholic fatty liver disease: a review of current understanding and future impact (Q35996525)

11 August 2017

1 reference

title

Nonalcoholic fatty liver disease: a review of current understanding and future impact (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

11 August 2017

0 references

1 reference

1 reference

Michael Charlton

1

1 reference

PubMed ID

15625647

11 August 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Clinical Gastroenterology and Hepatology

11 August 2017

1 reference

11 August 2017

2

1 reference

11 August 2017

1048-1058

1 reference

11 August 2017

12

1 reference

Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Adolescent obesity increases significantly in second and third generation U.S. immigrants: the National Longitudinal Study of Adolescent Health.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Overweight and obesity in the United States: prevalence and trends, 1960-1994

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Nonalcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Idiopathic steatohepatitis in childhood: a multicenter retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Nonalcoholic steatohepatitis: an expanded clinical entity.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Evaluation of the immune response to pneumococcal capsular polysaccharides.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

The utility of radiological imaging in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Hypoechoic lesions in the ‘bright liver': A reliable indicator of fatty change. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Liver fibrosis in overweight patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Steatohepatitis: a tale of two "hits"?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Apolipoprotein synthesis in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Animal models of steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Strategies and prospects for finding insulin resistance genes

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

1 reference

7 January 2021

New perspectives into the molecular pathogenesis and treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Genetics of type 2 diabetes and insulin resistance: knowledge from human studies

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Free fatty acids and pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Insulin resistance in relatives of NIDDM patients: the role of physical fitness and muscle metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Effect of dietary lipid on insulin action. Clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Drug-induced disorders of glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Rad: a member of the Ras family overexpressed in muscle of type II diabetic humans

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Relationship between serum leptin and fatty liver in Japanese male adolescent university students

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Serum leptin levels in patients with nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

ACRP30, a new hormone controlling fat and glucose metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

The hormone resistin links obesity to diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Pathogenesis of liver fibrosis: role of oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Persistent hyperaminotransferasemia resolving after weight reduction in obese children.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Effect on Hepatic Morphology of Treatment of Obesity by Fasting, Reducing Diets and Small-Bowel Bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Metformin reverses fatty liver disease in obese, leptin-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Choline deficiency: A cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

N-acetylcysteine in the treatment of non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994).

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Recurrence of nonalcoholic steatohepatitis following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

Metformin in non-alcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900440-9

7 January 2021

10.1016/S1542-3565(04)00440-9

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15625647